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Alan S. Maisel, MD,*† Lori B. Daniels, MD, MAS†
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Since the initial studies showing the usefulness of B-type natriuretic peptide for aiding in heart failure diagnosis,
a vast number of other clinical applications for this neurohormone have emerged. In addition to refining our ca-
pabilities to diagnose and prognosticate in acute heart failure, natriuretic peptides are now being used in outpa-
tient heart failure clinics, in screening programs, and in risk prediction algorithms in various settings. In just 10
years, B-type natriuretic peptide has gone from being an unknown biomarker to being one of the most useful in
cardiology and beyond. In this perspective piece, the investigators review what we have learned about using na-
triuretic peptides over the past 10 years and the anticipated advances in their use over the next decade.
(J Am Coll Cardiol 2012;60:277–82) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.057Naysayers abounded; not everyone initially grasped the
unmet need for a test to diagnose heart failure. B-type
natriuretic peptide (BNP) was first described by Japanese
researchers in 1988 (1), and when an early study, published
in 1994, showed that this biomarker could help distinguish
between cardiac and noncardiac causes of dyspnea, a seed
was planted (2). It was not until the publication of the
prospective, multinational Breathing Not Properly study in
2002, which convincingly showed the usefulness of BNP in
establishing or excluding a diagnosis of congestive heart
failure in patients presenting to emergency departments
with dyspnea, that BNP began to take off clinically (3).
Now, 10 years later, a PubMed search for “natriuretic
peptide” yields more than 25,000 results, and one would be
hard pressed to find an emergency department without
access to natriuretic peptide (NP) testing.
Since the initial studies showing the usefulness of NPs for
aiding in heart failure diagnosis, a vast number of other
clinical applications for these neurohormones have emerged.
In addition to refining our capabilities to diagnose and
prognosticate in acute heart failure (AHF), NPs are now
being used in outpatient heart failure clinics, in screening
programs, and in risk prediction algorithms in various
settings. In just 10 years, BNP has gone from being an
unknown biomarker to being one of the most useful in
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2012, accepted March 19, 2012.cardiology and beyond. In this perspective piece, we review
what we have learned about using NPs over the past 10 years
and the advances we anticipate in the use of NPs over the
next decade.
Acute Heart Failure
Diagnosis of acute heart failure. There is little dispute
about the usefulness of NPs in clarifying the differential
diagnosis of patients presenting with dyspnea. The physical
findings of AHF are not always present, and other tests such
as chest x-ray and echocardiography are insensitive measures
of acute elevations of filling pressures (4). Mistakes in
diagnosis can be costly, so rapid and accurate diagnostic
tests are important. NP testing is highly accurate in this
setting, with sensitivity being its major strength. A BNP
level  100 pg/ml or an N-terminal pro-BNP (NT-
proBNP) level  300 pg/ml can rule out AHF in 9 of 10
cases (3). Additionally, levels higher than 400 pg/ml are
highly specific for AHF, especially if this is a new diagnosis
in an untreated patient. The PRIDE (N-Terminal Pro-
BNP Investigation of Dyspnea in the Emergency Depart-
ment) study demonstrated equal value of NT-proBNP with
cut points related to patient age (5).
Valuable information continues to accumulate since
Breathing Not Properly. For instance, even if a physician
were to forgo an NP level to help with diagnosis because of
a high probability of AHF, NP levels still provide important
prognostic information. In ADHERE (Acute Decompen-
sated Heart Failure National Registry), the later the NP
level was drawn in the emergency department and the
higher that level was, the higher the risk for hospital
mortality (6). Indeed, NP levels perform better than physi-
cians’ assessments of heart failure severity (7). Many treat-
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BNP 10 Years Later: What We Have Learned July 24, 2012:277–82ment decisions are based in part
on the extent of elevation. Addi-
tionally, we have learned that NP
levels, when used as part of the
routine assessment of patients
with dyspnea, lead to significant
reductions in treatment costs,
highlighted by 3 days’ shorter
length of stay and a 26% reduc-
tion in overall costs (8). Newer NPs
such as midregion pro–atrial NP
have recently been shown to be as
good as other NPs, with possible
added value when diagnosis is indeterminate (9).
aveats. Along with the value of NPs in patients with
yspnea, we have also learned much about their limitations.
he major caveats of NPs are decreased levels in obese
atients, mild increases in those with renal impairment, and
idrange, nondiagnostic “gray-zone” levels (10–12). Van
immenade et al. (13) reported that patients with gray-zone
T-proBNP results were at higher risk for future events
ompared with those with negative results.
The issue of renal dysfunction is of particular importance,
ecause patients often present with acute cardiorenal syn-
romes. In most cases, even in the setting of reduced
lomerular filtration rates, NP levels are higher in patients
ith heart failure than in those without heart failure. A
atient’s baseline level may be especially important for
nterpretation in these settings (14,15).
To the intelligent physician, these caveats are easily under-
tood in the context of the rest of the illness. Nevertheless, we
re reminded that NPs should not be used as stand-alone tests
ut as adjuncts to the doctor’s armamentarium.
racking inpatients and discharge monitoring. Although
here have been no randomized trials of an NP-lowering
trategy in patients hospitalized with AHF, data and com-
on sense suggest the potential usefulness of this paradigm.
cute elevations of NP levels over baseline levels are
onsidered “wet NP levels.” With a relatively short half-life,
he hypervolemic “wet BNP” decreases rapidly as cardiac
lling pressures are reduced. The closer one gets to true
uvolemia, the lower the BNP approaches its “optivolemic”
evel. Patients discharged with BNP levels under 300 to 400
g/ml, whether it takes 2 days or 5 days, have a better
rognosis than those with higher levels (16,17). Although
here is no consensus as to the best ways to lower NP levels
n the hospital, consensus statements have suggested that 2
r 3 levels should be drawn during hospitalization: 1 at
dmission, 1 at discharge, and in some cases 1 during
reatment to ensure a downward trend (12,17,18). The
ischarge NP level may in fact be the most important level
f all (19). Not only do low levels predict less death and
eadmission at 30 days, but this level can be compared with
he level obtained if a patient returns to the emergency
epartment or clinic with symptoms of possible decompen-
Abbreviations
and Acronyms
AHF  acute heart failure
BNP  B-type natriuretic
peptide
CVD  cardiovascular
disease
NP  natriuretic peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptideation. Before routine hospital monitoring of NP levels can we added to guidelines, research much show clinical benefit
s well as effective algorithms.
utpatient Heart Failure
reventing readmission. The problems with high 30-day
eadmission rates cannot be overemphasized in the era of
iminished health care dollars. Preventative strategies in-
lude adequate discharge preparation (appropriate medica-
ion and dietary teaching, along with education about when
o report symptoms), early follow-up in the clinic, and
ccurate assessment of volume overload, the chief culprit for
arly readmissions. Studies have clearly demonstrated that
ongestion may precede symptoms by 7 to 10 days (20).
ecause NP release parallels increases in end-diastolic wall
tress, NPs are attractive targets for monitoring. A recent
rial demonstrated that discharged patients whose 30-day
NP levels are greater than their discharge levels are at
ighest risk for decompensation (19). With the advent of
ome monitoring of BNP with finger-stick technology
Alere Inc., San Diego, California), future studies will focus
n the feasibility of early intervention on the basis of a
ombination of weight gain and frequent home BNP
esting. Home testing also has the potential to favorably tilt
he cost-benefit ratio, though this too will need to be
valuated.
P-guided therapy. NP-guided therapy for treatment of
hronic heart failure has had its vocal share of advocates as
ell as detractors, depending on whether they interpret the
up as half full or half empty. Clearly, because heart failure
s one disease for which “personalized medicine” is lacking
e.g., for most drugs, the same dose is prescribed for most
atients), the prospect of combining biomarker-guided
herapy with “biomonitoring” of disease is appealing (21).
lthough many of the studies on biomarker-guided therapy
ave yielded equivocal and often controversial results, it is
enerally accepted that there is some benefit, especially in
hose under 75 years of age (22). However, a weakness of
any studies is that either NP levels were infrequently
easured, or, more important, little was done after they
ere measured. One recent study that did show a significant
enefit to biomarker-guided therapy was the PROTECT
Use of NT-proBNP Testing to Guide Heart Failure
herapy in the Outpatient Setting) study (23). Although
his was a single-center study, the investigators paid rigor-
us attention to lowering NT-proBNP levels. Indeed, the
0% drop in levels was associated with a near 50% drop in
vent rates. Future studies in this area should certainly
ttempt to achieve a vigorous lowering of NP levels, not by
percent drop but to a pre-specified low level.
creening
creening for heart disease. NP levels cannot absolutely
etermine who has or does not have subclinical cardiovas-
ular disease (CVD), but as time goes by, we are learning
ays to successfully incorporate NPs into various screening
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July 24, 2012:277–82 BNP 10 Years Later: What We Have Learnedalgorithms (Table 1). In the past 5 years, NPs have been
recognized by the European Society of Cardiology guide-
lines as useful agents for ruling out heart failure in a primary
care setting (24). The American College of Cardiology and
American Heart Association guidelines also have recog-
nized that elevated NP levels are associated with left
ventricular hypertrophy, reduced left ventricular systolic
function, left ventricular diastolic dysfunction, and elevated
filling pressures (25). Because NPs are sensitive to factors
such as age, sex, body mass index, renal function, and other
clinical factors, the use of a one-size-fits-all cut point for
ruling in or excluding heart disease may not be the best use
of the test. Recently, a multinational study of more than
5,000 primary care patients suggested that age-based cut
points for NT-proBNP considerably improved performance
compared with a single cut point, with a high negative
predictive value for ruling out decreased left ventricular
systolic function (26). Another way to improve screening
performance of NPs, as recently reported from the Dallas
Heart Study in an analysis of identifying stage B heart
failure, is to use them in conjunction with traditional risk
scores, rather than in isolation (27).
Clearly, the successful implementation of NPs to screen
for heart disease will hinge on targeting the appropriate
population. Screening tools are rarely indicated for everyone
regardless of age, sex, or other risk factors, even when the
aim is primary prevention. A more effective strategy is to
target patients with certain risk factors who are at somewhat
higher risk (28). Although studies have demonstrated that
NPs are not ideal for identifying patients with left ventric-
ular systolic dysfunction overall, performance among high-
risk men (age 50 years or with hypertension) was compa-
rable with the performance of other commonly used
screening tests, such as prostate-specific antigen screening
for prostate cancer, Papanicolaou smears for cervical cancer,
and mammography for breast cancer (29). A strategy
targeting moderate-risk or higher risk groups has a much
higher likelihood of success than does a shotgun approach
whereby every patient is evaluated.
Potential Screening andRisk Prediction Applications for Natriuretic PeptidesTable 1 Pote tial Screening andRisk Prediction Applications for Natriuretic Peptides
Application Status
Screening for stage A HF Not currently recommended
Screening for stage B HF Recognized as useful;
depends on population
Ruling out HF in primary care setting (stage C) In guidelines
Risk prediction in stable coronary heart disease Useful
Risk prediction in unstable coronary heart disease Useful
Risk prediction in HF Useful
Risk prediction in the community Potentially useful; depends
on population
Pre-operative risk assessment Potentially useful
Risk prediction with cardiotoxic chemotherapy Potentially useful
Risk prediction in valvular heart disease Potentially usefulHF  heart failure.Cardiovascular risk prediction. Since BNP became ac-
cepted in clinical practice 10 years ago, additional studies
have informed us of its utility in cardiovascular risk predic-
tion across a variety of clinical scenarios. Early on, it was
established that BNP is useful for risk prediction in patients
with pre-existing cardiac disease, including stable (30,31)
nd unstable coronary heart disease (32) and heart failure
11). Simultaneously, large community-based studies have
ocumented that NPs can improve CVD risk prediction
bove and beyond traditional CVD risk factors, even in
atients without heart failure or coronary disease at baseline.
ang et al. (33) initially reported this in the Framingham
ffspring cohort, in which BNP levels were associated with
n increased risk for death and first cardiovascular event over
mean 5.2 years of follow-up. The results have been
olstered by similar findings in a number of other cohorts.
ore recently, a study of Olmstead County, Minnesota,
esidents suggested that the prognostic utility of NPs in the
eneral community may be limited to patients with risk
actors for CVD and may not provide a significant level of
rognostic information in completely healthy subjects, even
hen levels are greater than the 80th percentile (34). This is
onsistent with the previously demonstrated concept that
creening may be most cost effective when targeted to
igher risk populations (28).
Areas that are evolving rapidly in the use of NPs to predict
VD risk include pre-operative evaluations. Including an NP
n risk assessment algorithms is improving predictive perfor-
ance for the risk for mortality and cardiovascular complica-
ions after vascular and other procedures (35–37).
The potential for NPs to help identify chemotherapy
atients at risk for drug-induced cardiotoxicity is another
rea of active exploration. Persistently elevated levels of NPs
re associated with the development of early and late
yocardial dysfunction after chemotherapy with anthracy-
lines and other cardiotoxic agents, though there seems to
e a good deal of overlap in NP levels between those who
evelop cardiotoxicity and those who do not (38–41).
Clinical trials are needed to determine whether early iden-
tification and treatment of these patients can improve
outcomes.
NP levels are also being increasingly used to assist with
risk prediction and assessment of patients with valvular
heart disease. In the setting of severe organic mitral regur-
gitation, a normal NP level has a very high negative
predictive value for the development of symptoms or dete-
rioration of left ventricular function over the following 6
months (42), whereas elevated levels are associated with
increased risk for heart failure, left ventricular dysfunction,
or death (43). In patients with aortic stenosis, NP levels are
consistently related to the severity of the disease and
symptom status (44). In those with severe, asymptomatic
aortic stenosis, an elevated or rising NP level is predictive of
short-term need for valve replacement and of worse out-
comes (45) and may therefore help with the timing of
surgery in patients with equivocal symptoms. In addition,
f
m
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BNP 10 Years Later: What We Have Learned July 24, 2012:277–82elevated NP levels independently predict perioperative com-
plications of aortic valve replacement surgery, as well as
major adverse cardiac and cerebrovascular events within 36
months after aortic valve replacement (46). A BNP level is
also helpful in low-flow, low-gradient aortic stenosis, in
which levels 550 pg/ml predict poor outcomes indepen-
dent of contractile reserve (47). Similarly, in chronic, severe
aortic regurgitation, an elevated BNP level (130 pg/ml)
predicts poor outcomes even when patients have normal left
ventricular function and are asymptomatic (48). Thus, NPs
are becoming an invaluable aid to clinicians caring for
patients with challenging presentations of a variety of
valvular heart diseases.
In summary, one of the most rapid and successful areas of
expansion in the use of NP levels over the past 10 years has
been in risk prediction in a multitude of clinical settings
beyond the one originally targeted, AHF. We anticipate
that this application will continue to evolve and grow.
Outpatient risk profiling with multimarker panels. Indi-
vidual biomarkers, including NPs, have certain shortcom-
ings that have limited or slowed their clinical uptake as risk
predictors in outpatient settings. Variability in day-to-day
values and poor predictive values at the level of the individ-
ual patient have been difficult obstacles to overcome in lower
risk outpatient populations. Creating a risk profile by
combining NP levels with other biomarkers from distinct
pathophysiologic pathways has the potential to overcome
some of this and to improve risk stratification. However,
results using this approach have been mixed.
Several studies have evaluated multimarker panels for
predicting CVD in the community. Some found statistically
significant though clinically modest improvements in pre-
diction by using multiple biomarkers compared with using
traditional risk factors alone (49–51), while a few reported
substantial improvements in risk prediction with a multimarker
approach (52–55). NP levels have been the cornerstone of the
multimarker approach; nearly all of the successful multimarker
panels have included NP measurements.
A similar pattern has emerged in secondary prevention
populations. A subanalysis from the HOPE (Heart Out-
comes Prevention Evaluation) study evaluated 11 biomark-
ers (including 9 inflammatory markers plus NT-proBNP
and microalbuminuria) in 3,199 patients with histories of
coronary artery disease, peripheral vascular disease, diabetes,
or stroke (56). After a mean 4.5 years of follow-up, only
NT-proBNP provided incremental prognostic information
for the prediction of cardiovascular events compared with a
traditional risk factor model. Although several inflammatory
markers were significantly related to future cardiovascular
risk, they added little additional prognostic information to
the traditional markers. A substudy from the AtheroGene
cohort of patients with stable coronary artery disease eval-
uated a multimarker panel that included NT-proBNP,
growth differentiation factor-15, midregion pro–atrial NP,
cystatin C, and midregion pro-adrenomedullin, plus 6 other
markers that proved inconsequential (57). The combinationof all 5 markers improved risk stratification (the net reclas-
sification index) for nonfatal myocardial infarction or car-
diovascular death, though the 2 strongest markers, NT-
proBNP and growth differentiation factor-15, were the only
ones to significantly improve discrimination (the C-statistic).
Notably, most currently published studies were performed
before the introduction of high-sensitivity cardiac troponin
assays, and it remains to be seen whether this latest comer
will integrate with NPs to improve risk stratification.
Table 2 highlights potential components of a multi-
marker panel. A consistent theme in multimarker panels for
outpatient risk profiling, in both primary and secondary
heart disease prevention populations, is the central role that
NPs play. In the past 10 years, NPs have evolved from their
initial role in the diagnosis of acute patients to a more
ubiquitous role as a prognostic aid in both inpatients and
outpatients. In the next 10 years, new biomarkers are likely
to emerge and share the spotlight, but NP levels are unlikely
to be cast aside by any of them.
Conclusion: The Next 5 Years
Figure 1 conceptually predicts where we will be in NP
testing 5 years from now, compared with present times. As
the wealth of NP data continue to accumulate, we expect to
see progressively more clinical applications for NPs, as well
as increased acceptance by practicing clinicians.
Potential Components of aMultim rker Panel for Cardiovascular Risk ProfilingTable 2 otential omp nents of aMultimarker Panel for Cardiovascular Risk Profiling
Markers of myocardial strain
BNP, NT-proBNP, MR-proANP, osteoprotegerin, MR-proADM, copeptin
Markers of myocardial cell damage
Sensitive cardiac troponin, creatine phosphokinase–MB, myoglobin
Markers of ischemia
Ischemia-modified albumin, heart-type fatty acid–binding protein, choline, MPO
Markers of inflammation and vascular damage
CRP, IL-6, TNF-alpha, adiponectin, pentraxin-3
Markers of fibrosis and remodeling
ST2, galectin-3, MMPs, tissue inhibitors of MMPs, collagen propeptides
(procollagen-3)
Markers of atherosclerosis and unstable plaque
GDF-15, NGAL, Lp(a), Lp-PLA2, OxLDL, MPO, placental growth factor, PAPP-A,
secretory phospholipase A2, soluble fms-like tyrosine kinase-1,
soluble ICAM-1, endothelin, osteopontin
Renal markers
Cystatin C, NGAL, creatinine, urinary albumin/creatinine ratio, KIM-1,
beta-trace protein
Genetic markers
Single-nucleotide polymorphisms, structural variants
Categories are not mutually exclusive.
BNP  B-type natriuretic peptide; CRP  C-reactive protein; GDF-15  growth differentiation
actor-15; ICAM  intercellular adhesion molecule; IL-6  interleukin-6; KIM-1  kidney injury
arker–1; Lp(a)  lipoprotein(a); Lp-PLA2  lipoprotein phospholipase A2; MMP  matrix
metalloproteinase; MPO  myeloperoxidase; MR-proADM  midregion pro-adrenomedullin; MR-
proANP  midregion pro–atrial natriuretic peptide; NGAL  neutrophil gelatinase–associated
lipocalin; NT-proBNP  N-terminal pro–B-type natriuretic peptide; OxLDL  oxidized low-density
lipoprotein; PAPP-A  pregnancy-associated plasma protein A; TNF  tumor necrosis factor.
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